Toxicity of a Novel Herbomineral Preparation Las01 on Human Cancer Cell Lines and Its Safety Profile in Humans and Animals

Table 4

Effect of administration of Las01 on biochemical parameters of cancer patients.

	Normal range	Pretreatment	1 year after treatment
LFT
Serum bilirubin (T)	0.2–1.0 mg/dL	0.75	0.78
Serum bilirubin (D)	0.0–0.3; mg/dL	0.32	0.34
Bilirubin (ID)	0.1–1.0; mg/dL	0.43	0.44
SGOT	0–37 (M) 0–31 (F) lu/L	31	28
SGPT	0–37 (M) 0–31 (F) lu/L	29	30
S-Alkaline phosphatase	100–275 lu/L	192	185
KFT
Blood urea	15–50 mg%	22.6	22.7
S. uric acid	2.0–6.0 mg%	3.9	3.82
Creatinine	0.0–2.0 mg%	0.6	0.7
RBS	70–150 mg%	75	80
Total protein	6.0–9.0 mg%	7.2	7.1
Albumin	3.0–6.0 gm%	3.2	3.0
Globulin	2.0–5.0 gm%	4.0	4.1
Electrolyte
Serum sodium	135–145 meq/L	140.2	141.1
Serum potassium	3.0–6.0 meq/L	4.21	5.0